See more : Banzai International, Inc. (BNZIW) Income Statement Analysis – Financial Results
Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Global Links Corp. (GLCO) Income Statement Analysis – Financial Results
- Caina Technology Co., Ltd. (301122.SZ) Income Statement Analysis – Financial Results
- Sime Darby Plantation Berhad (SDPNF) Income Statement Analysis – Financial Results
- Beijing Comens New Materials Co.,Ltd. (300200.SZ) Income Statement Analysis – Financial Results
- China Southern Airlines Company Limited (CHKIF) Income Statement Analysis – Financial Results
Sanofi (SNY)
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.03B | 45.39B | 39.18B | 37.37B | 37.63B | 35.68B | 36.22B | 34.70B | 34.86B | 32.00B | 31.29B | 35.96B | 35.06B | 32.04B | 30.75B | 28.82B | 29.25B | 29.49B | 28.49B | 15.03B | 8.03B | 7.46B | 6.49B | 5.96B | 5.35B |
| Cost of Revenue | 14.24B | 13.69B | 12.26B | 12.16B | 11.98B | 11.32B | 11.45B | 10.70B | 10.92B | 10.23B | 10.29B | 11.08B | 10.90B | 8.72B | 7.88B | 7.34B | 7.58B | 7.59B | 7.56B | 3.75B | 1.43B | 1.38B | 1.25B | 1.44B | 1.49B |
| Gross Profit | 31.80B | 31.70B | 26.92B | 25.21B | 25.66B | 24.36B | 24.77B | 24.00B | 23.94B | 21.77B | 21.00B | 24.88B | 24.16B | 23.32B | 22.87B | 21.48B | 21.67B | 21.90B | 20.93B | 11.28B | 6.61B | 6.08B | 5.24B | 4.52B | 3.86B |
| Gross Profit Ratio | 69.07% | 69.83% | 68.72% | 67.47% | 68.18% | 68.27% | 68.40% | 69.16% | 68.68% | 68.03% | 67.10% | 69.20% | 68.90% | 72.79% | 74.37% | 74.55% | 74.08% | 74.27% | 73.47% | 75.05% | 82.26% | 81.50% | 80.69% | 75.82% | 72.11% |
| Research & Development | 6.73B | 6.71B | 5.69B | 5.53B | 6.02B | 6.35B | 5.57B | 5.23B | 5.08B | 4.67B | 4.61B | 4.91B | 4.81B | 4.40B | 4.58B | 4.58B | 4.54B | 4.43B | 4.04B | 7.45B | 1.31B | 1.22B | 1.03B | 945.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00M | 106.00M | 106.00M | 114.00M | -542.00M | -495.00M | 182.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 9.39B | 9.88B | 9.86B | 10.06B | 9.49B | 9.38B | 9.11B | 8.60B | 8.95B | 8.54B | 7.57B | 7.33B | 7.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.77B | 10.54B | 9.56B | 9.39B | 9.88B | 9.93B | 10.16B | 9.59B | 9.50B | 8.57B | 8.11B | 9.13B | 8.54B | 7.57B | 7.33B | 7.17B | 7.87B | 8.02B | 8.24B | 4.50B | 2.47B | 2.43B | 2.31B | 2.02B | 1.89B |
| Other Expenses | 6.45B | 2.57B | 2.53B | 2.40B | 2.53B | 1.70B | 1.66B | 1.65B | 2.23B | 3.02B | 3.13B | 3.02B | 3.62B | 3.58B | 3.14B | -23.00M | 3.20B | 3.45B | 2.93B | -360.73M | -246.94M | -189.64M | -208.00M | -17.00M | 995.00M |
| Operating Expenses | 23.94B | 19.81B | 17.77B | 17.32B | 18.43B | 17.99B | 17.39B | 16.48B | 16.81B | 16.25B | 15.84B | 17.05B | 16.97B | 15.55B | 15.05B | 11.72B | 15.61B | 15.90B | 15.21B | 11.59B | 3.54B | 3.46B | 3.13B | 2.94B | 2.89B |
| Cost & Expenses | 38.16B | -7.29B | 30.03B | 29.48B | 30.41B | -7.73B | -7.42B | -7.18B | -7.44B | -5.64B | -5.86B | -7.29B | 27.87B | 24.27B | 22.93B | 19.06B | 23.20B | 23.49B | 22.77B | 15.34B | 4.96B | 4.84B | 4.38B | 4.39B | 4.38B |
| Interest Income | 546.00M | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M | 147.00M | 68.00M | 178.00M | 193.00M | 109.00M | 93.00M | 140.00M | 105.00M | 24.00M | 65.00M | 190.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.09B | 461.00M | 368.00M | 390.00M | 444.00M | 495.00M | 420.00M | 924.00M | 559.00M | 598.00M | 609.00M | 751.00M | 552.00M | 467.00M | 324.00M | 335.00M | 329.00M | 1.54B | 4.71B | 2.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.78B | 3.70B | 3.13B | 3.27B | 3.75B | 3.46B | 3.15B | 2.99B | -2.48B | -2.75B | -3.39B | -3.20B | 4.91B | 5.44B | 5.00B | 245.00M | 4.48B | 6.73B | 5.95B | 2.52B | 117.52M | 179.16M | 301.00M | 241.00M | 236.00M |
| EBITDA | 12.00B | 14.06B | 11.29B | 17.51B | 7.11B | 9.36B | 10.28B | 10.36B | 10.23B | 9.87B | 9.62B | 11.43B | 10.64B | 11.40B | 11.40B | 10.48B | 10.40B | 12.12B | 11.67B | 2.25B | 3.19B | 3.00B | 2.41B | 1.82B | 1.21B |
| EBITDA Ratio | 26.06% | 30.98% | 27.47% | 26.13% | 26.15% | 26.24% | 28.38% | 29.86% | 29.36% | 30.84% | 30.74% | 34.77% | 30.35% | 35.59% | 36.98% | 34.73% | 35.56% | 42.26% | 47.01% | 14.99% | 39.67% | 37.49% | 37.10% | 30.49% | 22.56% |
| Operating Income | 7.88B | 16.79B | 8.13B | 8.08B | 7.69B | 12.43B | 12.01B | 12.34B | 12.71B | 12.62B | 13.01B | 15.70B | 5.73B | 5.96B | 6.37B | 9.76B | 5.92B | 5.73B | 7.45B | -262.61M | 3.07B | 2.62B | 2.11B | 1.58B | 971.00M |
| Operating Income Ratio | 17.11% | 37.00% | 20.74% | 21.63% | 20.45% | 34.84% | 33.15% | 35.57% | 36.46% | 39.45% | 41.58% | 43.67% | 16.35% | 18.61% | 20.70% | 33.88% | 20.24% | 19.43% | 26.13% | -1.75% | 38.21% | 35.09% | 32.46% | 26.45% | 18.15% |
| Total Other Income/Expenses | -722.00M | -166.00M | -328.00M | 24.00M | -229.00M | 228.00M | -188.00M | -720.00M | -403.00M | -458.00M | -459.00M | -1.81B | -542.00M | -362.00M | -300.00M | -232.00M | -139.00M | -981.21M | -2.11B | -588.67M | 58.76M | -108.64M | 34.00M | -17.00M | -48.00M |
| Income Before Tax | 7.15B | 10.49B | 7.80B | 13.80B | 2.82B | 4.90B | 5.62B | 5.81B | 5.22B | 5.61B | 4.52B | 6.17B | 5.32B | 5.60B | 6.07B | 9.49B | 5.78B | 4.75B | 2.64B | -1.84B | 3.13B | 2.51B | 2.14B | 1.56B | 0.00 |
| Income Before Tax Ratio | 15.54% | 23.11% | 19.91% | 36.94% | 7.50% | 13.75% | 15.50% | 16.75% | 14.98% | 17.52% | 14.45% | 17.15% | 15.17% | 17.48% | 19.73% | 32.94% | 19.76% | 16.10% | 9.27% | -12.25% | 38.94% | 33.63% | 32.98% | 26.16% | 0.00% |
| Income Tax Expense | 1.60B | 2.01B | 1.56B | 1.81B | 139.00M | 481.00M | 1.72B | 1.33B | 709.00M | 1.21B | 726.00M | 1.11B | 455.00M | 1.24B | 1.36B | 2.76B | 687.93M | 800.12M | 477.04M | 818.09M | 1.06B | 747.13M | 842.00M | 611.00M | 346.00M |
| Net Income | 5.40B | 8.37B | 6.22B | 12.29B | 2.81B | 4.31B | 3.89B | 4.71B | 4.29B | 4.39B | 3.72B | 4.97B | 5.69B | 4.36B | 5.27B | 7.19B | 5.27B | 4.01B | 2.26B | -2.66B | 2.07B | 1.76B | 1.59B | 985.00M | 625.00M |
| Net Income Ratio | 11.73% | 18.44% | 15.89% | 32.90% | 7.46% | 12.07% | 10.75% | 13.57% | 12.30% | 13.72% | 11.88% | 13.81% | 16.24% | 13.60% | 17.12% | 24.94% | 18.02% | 13.58% | 7.92% | -17.70% | 25.80% | 23.61% | 24.43% | 16.52% | 11.68% |
| EPS | 4.31 | 6.69 | 4.97 | 9.81 | 2.33 | 3.45 | 3.08 | 3.42 | 3.38 | 3.25 | 2.75 | 3.70 | 4.27 | 3.34 | 4.03 | 2.94 | 3.91 | 2.97 | 1.68 | -2.92 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| EPS Diluted | 4.30 | 6.66 | 4.95 | 9.76 | 2.31 | 3.43 | 3.07 | 3.39 | 3.34 | 3.21 | 2.71 | 3.68 | 4.26 | 3.33 | 4.03 | 2.94 | 3.89 | 2.95 | 1.67 | -2.91 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| Weighted Avg Shares Out | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.29B | 1.32B | 1.32B | 1.32B | 1.33B | 1.32B | 1.31B | 1.31B | 1.31B | 1.35B | 1.35B | 1.34B | 910.30M | 702.75M | 727.69M | 731.71M | 731.23M | 730.78M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.32B | 1.33B | 1.34B | 1.33B | 1.33B | 1.31B | 1.31B | 1.31B | 1.35B | 1.36B | 1.35B | 914.80M | 705.12M | 729.27M | 731.71M | 731.23M | 730.78M |
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi Q3 earnings beat market view, boosted by vaccine sales
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
French govt set to take stake in Sanofi unit after PE sale
Source: https://incomestatements.info
Category: Stock Reports